MWG Biotech receives Frost & Sullivan 2004 Technology Innovation Award for its Microarray Technology
Ebersberg. MWG Biotech AG has received the renowned Frost & Sullivan 2004 Technology Innovation Award in the field of microarray technology. The Award recognises MWG Biotech's high degree of technological innovation and the strong commercial potential for its HPSF® synthesis technology in microarray applications. This technology is proven to produce high quality (purified and salt-free) oligonucleotides much faster when compared to existing HPLC based approaches.
The Award also recognises MWG Biotech's ongoing technological achievement and rapid process improvement. In the award text Frost & Sullivan says, "For instance, [MWG Biotech] is currently developing MWG-HYPUR oligos. The process is based on a non-toxic hydrogel purification technique that removes n-1 products and depurinations from short and longmer oligonucleotides. When introduced, this technology is likely to outperform conventional polyacrylamide gel electrophoresis in terms of both quality and reproducibility".
"We are extremely proud of this Award," says Thomas Becker, CEO of MWG Biotech AG. "It clearly proves our innovative strength and the market leadership of our oligonucleotides as well as the valuable contribution they make to the production of our reliable, high quality MWG catalog and custom microarrays."
Frost & Sullivan's Award for Technology Innovation is bestowed upon a company that has carried out new research which has resulted in innovations that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The Award recognises the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavour.
Other news from the department research and development
